Key result
Simvastatin daily increased ex vivo platelet size during collagen and cold exposure by 2.6% and 1.7%, respectively, compared to placebo in patients with type 2 diabetes.
Why the study?
Does simvastatin 80 mg daily reduce platelet size in response to ex vivo stimuli in subjects with type 2 diabetes and mixed dyslipidemia?
RCT (n=12)
Single-blind
Does simvastatin 80 mg daily reduce platelet size in response to ex vivo stimuli in subjects with type 2 diabetes and mixed dyslipidemia?
High-dose simvastatin unexpectedly increased ex vivo platelet size in response to certain stimuli, suggesting that some of its effects on platelets may not be anti-atherogenic.
Answers are grounded in this paper and cite their sources.
High-dose simvastatin may increase ex vivo platelet size in type 2 diabetes; leaves open net effects on atherothrombosis.
Statins reduce coronary heart disease risk by altering blood lipids and other mechanisms. One of the possible other mechanisms is through an effect on thrombosis. We assessed the effect of simvastatin 80 mg daily versus placebo given in a single blind crossover fashion on platelet size in response to standard ex vivo stimuli, a surrogate for platelet activation, in 12 subjects with type 2 diabetes and mixed dyslipidemia. Exposure to collagen, cold, and heat caused the expected changes in platelet volume. Contrary to our expectations, ex vivo platelet size during collagen and cold exposure increased by 2.6 and 1.7%, respectively (P < 0.05), during simvastatin treatment as opposed to the placebo period. We conclude that some of the effects of high dose simvastatin therapy on platelets may not necessarily be anti-atherogenic.
No takes yet. Share an insight, caveat, or question.
Isley et al. (2006) conducted an RCT in Type 2 diabetes mellitus and mixed dyslipidemia (n=12). Simvastatin vs. Placebo was evaluated on Platelet size in response to standard ex vivo stimuli (collagen and cold exposure) (2.6% and 1.7% increase, p=<0.05). Simvastatin daily increased ex vivo platelet size during collagen and cold exposure by 2.6% and 1.7%, respectively, compared to placebo in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: